Data on Ariad Pharmaceuticals, Inc.'s Oncology Pipeline to Be Presented at the 2010 ASCO Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that new data on AP24534, its investigational pan-BCR-ABL inhibitor, and ridaforolimus, its investigational mTOR inhibitor being developed by Merck, Sharpe & Dohme Corp., have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois being held June 4 to 8, 2010.